Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2011-02-04 17:45 |
VIVALIS DECLARATION D'ACTIONS ET DROITS DE VOTE
|
English | 50.6 KB | ||
| 2011-01-27 17:40 |
VIVALIS : 2010 on target and strong revenue growth
|
English | 91.9 KB | ||
| 2011-01-27 17:40 |
VIVALIS : Objectifs 2010 atteints et forte hausse du produits des activités ord…
|
French | 93.3 KB | ||
| 2011-01-25 17:40 |
VIVALIS communique son agenda financier 2011
|
French | 83.0 KB | ||
| 2011-01-25 17:40 |
VIVALIS announces its 2011 financial calendar
|
English | 75.6 KB | ||
| 2011-01-11 17:40 |
VIVALIS AND MERIAL SIGN A NEW COMMERCIAL LICENSE FOR THE USE OF THE EB66® CELL …
|
English | 75.3 KB | ||
| 2011-01-11 17:40 |
VIVALIS ET MERIAL SIGNENT UNE NOUVELLE LICENCE COMMERCIALE D'UTILISATION DE LA …
|
French | 80.3 KB | ||
| 2011-01-07 17:46 |
VIVALIS BILAN SEMESTRIEL CONTRAT DE LIQUIDITE
|
English | 193.6 KB | ||
| 2011-01-07 17:45 |
VIVALIS ACTIONS ET DROITS DE VOTE
|
English | 52.7 KB | ||
| 2011-01-05 17:40 |
VIVALIS ET SANOFI PASTEUR INITIENT LE SECOND PROGRAMME DE DECOUVERTE D'ANTICORP…
|
French | 83.3 KB | ||
| 2011-01-05 17:40 |
VIVALIS AND SANOFI PASTEUR INITIATE SECOND HUMAN MONOCLONAL ANTIBODY DISCOVERY …
|
English | 89.7 KB | ||
| 2010-12-06 17:50 |
VIVALIS - DECLARATION ACTIONS ET DROIT DE VOTE
|
French | 52.0 KB | ||
| 2010-12-06 17:45 |
VIVALIS ACTIONS ET DROIT DE VOTE
|
English | 52.1 KB | ||
| 2010-11-24 07:30 |
VIVALIS ACHIEVES A SIGNIFICANT MILESTONE WITH THE ACCEPTANCE OF AN INVESTIGATIO…
|
English | 90.0 KB | ||
| 2010-11-24 07:30 |
VIVALIS FRANCHIT UNE ETAPE MAJEURE : ACCEPTATION DE LANCEMENT DES ESSAIS CLINI…
|
French | 84.4 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
